1
. The affinity of anti-LDL to the lipoprotein from the blood of atherosclerotic patients, as well as to LDL desialylated in vitro with neuraminidase, was much higher. Anti-LDL increased the uptake of LDL by cultured aortic cells by approximately 2.5-fold and substantially increased intracellular lipid accumulation. The obtained data suggest that autoantibodies against LDL are an essential factor of blood plasma responsible for its atherogenic potential. (Arteriosclerosis and Thrombosis 1991;! 1:316-326) R ecently, we 1 -2 have found that the blood serum of coronary heart disease (CUD) patients with angiographically documented coronary atherosclerosis, as well as patients' plasma and plasma-derived low density lipoprotein (LDL), causes atherosclerosis-related alterations in cultures of human aortic intimal cells, which are manifested by the accumulation of cellular lipid, mostly free and esterified cholesterol. The serum-or LDL-induced deposition of lipids is accompanied by enhanced proliferation as well as increased synthesis of collagen, glycosaminoglycans, and total protein. 3 ' 4 Serum and LDL of most healthy donors were unable to stimulate atherosclerosis-related processes in cultured cells.
1 - 6 We 7 have established that the patients' LDL causing intracellular lipid accumulation differs from native LDL of healthy donors by a low sialic acid content. On the other hand, desialylation of native LDL derived from healthy donors by neuraminidase treatment led to lipid accumulation in cultured human aortic cells. 78 These data suggest that it is desialylation that determines the capacity of the patients' LDL to accumulate cellular lipids.
We 1 have recently shown that desialylated LDL is not the sole factor in patients' blood plasma responsible for its ability to cause atherosclerosis-related manifestations at the arterial cell level. From the blood of atherosclerotic patients, we 9 have isolated immunoglobulin Gs (IgGs) having a higher affinity for LDL desialylated in vitro and for LDL obtained from patients' blood than for native LDL derived from the blood of healthy donors. These IgGs substantially increased the ability of patients' LDL to induce the accumulation of cellular cholesterol. 9 We assumed that Igs isolated from patients' blood samples are represented by autoantibodies against modified LDL. This study was undertaken to reveal the characteristics of these IgGs and to investigate their effect on the LDL-mediated accumulation of lipids in cultured subendothelial intimal cells of the human aorta.
Methods

Reagents
The reagents were purchased from Sigma Chemical Co., St. Louis, Mo., unless stated otherwise.
Serum
After an overnight fast, blood was drawn from the ulnar vein into plastic tubes and incubated for 1 hour at 37°C. Sera were obtained by repeated centrifugation at 3,000 rpm for 15 minutes. We selected the blood sera of 15 CHD patients with angiographically documented coronary atherosclerosis and the sera of 15 healthy donors who were chosen on the basis of a single criterion, that is, the presence or absence, in this particular serum, of the ability to induce the accumulation of cholesterol in cultured cells. All the patients' sera selected were capable of inducing cholesterol accumulation, while all the sera of healthy donors were not capable of doing so. The characteristics of CHD patients and healthy donors have been described in detail elsewhere. 1 -2 Characteristics such as age and sex in the groups of healthy donors and patients were similar. None of the donors had diabetes mellitus. The mean cholesterol level in both types of sera was the same: 186±4 mg/dl for patients and 176 ±6 mg/dl for healthy subjects. Healthy donors had no signs of heart disease as determined by epidemiological criteria (12- ) was isolated from the plasma obtained from patients and healthy donors according to the conventional method of ultracentrifugation in a stepwise gradient of NaBr 10 as described elsewhere.
12 Lipoprotein(a) (Lp[a]) was isolated by immunoaffinity chromatography involving an anti-apo(a)-Sepharose affinity column according to Gaubatz et al. 11 LDLs obtained from healthy donors were modified by acetylation, 12 glycosylation, 13 oxidation in the presence of Cu 2+ , 14 and malondialdehyde (MDA) alteration. 15 Desialylation of LDL was performed by agarose-bound neuraminidase (catalog No. N-4883) treatment for 3 hours at 37°C according to Camejo et al. 16 as described earlier.
7 -8 As a result of this procedure, LDL lost 70% of sialic acid (determined according to Warren 17 ) . As a result of glycosylation, 6% of the apo B lysine residues were modified (determined according to Witztum et al 18 ). MDA treatment resulted in the modification of 54% lysine residues (determined according to Yagi 19 ).
The MDA content of the LDL preparations obtained from healthy donors was 1.4±0.2 nmol/mg apo B, LDL from atherosclerotic patients was 1.6±0.2 nmol/mg apo B, and oxidized lipoprotein preparations were 16.2±0.5 nmol/mg apo B (as determined according to Yagi 19 ). Lipoprotein preparations and the lipoprotein-deficient serum were dialyzed for 24 hours against 2,000 volumes of phosphate-buffered saline (PBS), sterilized by filtration, and stored at 4°C. Lipoproteins were used within 1-4 days after preparation. Ah" lipoprotein preparations were filtered (pore size, 0.45 /xm) immediately before addition to the culture. To investigate the cellular metabolism of LDL, lipoprotein was iodinated by the iodine monochloride method. 20 More than 98% of 125 I in the labeled lipoprotein preparation was precipitated in 10% trichloroacetic acid (TCA). Cells were incubated with labeled lipoprotein for 6 hours at 37 C C. After incubation, an aliquot of the culture medium was taken to determine LDL degradation by the presence of the TCA-soluble (noniodide) I25 I.
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To determine the uptake, cells were rinsed three times with PBS containing 0.2% albumin and seven times with PBS, after which they were dissolved in 0.1N NaOH to measure the radioactivity.
Cell Cultures
Cells were obtained from fresh segments of thoracic aortas taken at autopsy from 40-to 60-year-old men. Subendothelial cells were isolated from a grossly normal intima by dispersion with collagenase and were cultured as described elsewhere. 22 A suspension of the isolated cells was resuspended in the growth medium containing Medium 199, 10% fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 100 ng/ml streptomycin, and 2.5 /xg/ml fungizone (all reagents from GIBCO, Grand Island, N.Y.) and seeded into Linbro 24-well tissue culture plates (Flow Laboratories Ltd., Irvine, U.K.) with a density of 2 to 4x10* cells/cm 2 of the growth area. The cells were cultured at 37°C in an atmosphere of 95% air/5% CO 2 in a humidified CO 2 incubator. The medium was changed every day. All additions were diluted to the final concentration with Medium 199. The primary cultures contained a mixed cell population made up primarily of cells of smooth muscle origin. 22 It has been shown that by formal criteria (staining with antibodies against smooth muscle myosin, ultrastructural characteristics), these cells can be classified into typical and so-called modified smooth muscle cells. 
Lipids
Before lipid determination, cells were rinsed three times with PBS, treated with 0.025% trypsin-EDTA for 5 minutes, and washed with PBS five times (all reagents were from GIBCO). The cells were removed from the substrate with 0.25% trypsin-EDTA and washed twice by centrifugation (200g, 10 minutes). Lipids were extracted from cells with a chloroform/methanol mixture (1:2, vol/vol) according to Bligh and Dyer. 27 The total cholesterol content in the lipid extracts was determined using the Boehringer Mannheim Monotest, cholesterol CHOD-PAP method (Boehringer Mannheim GmbH, Mannheim, F.R.G.). Cellular phospholipids, triglycerides, free cholesterol, and cholesteryl esters were separated by thin-layer chromatography and measured by scanning densitometry as described earlier. 22 Using light and electron microscopy, 25 ' 26 we have demonstrated that an increase of cellular lipids is associated with the appearance of intracellular lipid inclusions.
Electrophoresis and Immunoblotting
Electrophoretic fractionation of serum proteins was performed according to Laemmli 28 with a 3% concentrating polyacrylamide gel and a separating polyacrylamide gel gradient (3-15%). Two microliters serum was diluted in 50 fi\ 40 mM Tris HC1, 10 mM EDTA, 4% sodium dodecyl sulfate (SDS), 5% /3-mercaptoethanol, and 20% glycerol (pH 7.0). After electrophoretic separation for 14-16 hours, proteins were transferred onto nitrocellulose (Bio-Rad Laboratories, Richmond, Calif.) at a constant current (0.5 A/3 hours). 29 Nitrocellulose transfers were blocked with 50 mM Tris HC1 (pH 7.5) containing 0.5 M NaCl, 0.05% Tween-20, 2% bovine serum albumin (BSA), and 0.3% gelatin. Nitrocellulose strips were incubated for 3 hours with sera from healthy subjects and atherosclerotic patients diluted 30-fold with a blocking buffer as well as with the isolated human IgGs, which have an affinity for LDL (see below), or murine monoclonal antibody against human apo B obtained as described elsewhere. 26 After they were washed in 50 mM Tris HC1 (pH 7.5) with 0.5 M NaCl and 0.05% Tween-20, peroxidase-labeled anti-human and anti-mouse goat antibodies (Amersham International pic, Amersham, U.K.) were incubated with respective replicas for 1 hour. This was followed by washing and an incubation in 0.05% 4-chloro-lnaphthol and 0.03% H 2 O 2 in 50 mM Tris HC1, pH 7.5.
Immunoglobidin G Isolation
IgGs were isolated from the pooled blood sera of healthy donors and CHD patients by precipitation with 33% saturated ammonium sulfate and subsequent ionexchange chromatography on diethylaminoethyl cellulose DE-52 (Whatman Ltd., Maidstone, U.K.). 30 The
Ig content was determined immunochemically using Orion kits (Orion Diagnostica, Espoo, Finland).
Anti-Low Density Lipoprotein Purification
IgGs having an affinity for LDL (anti-LDL) were purified by affinity chromatography on a column with immobilized LDL. LDL immobilization on BrCNactivated Sepharose CL 4B was performed as described earlier. 1 Twenty to 30 milligrams of the total IgG fraction was applied to a column containing 10 ml LDL-Sepharose. The column was rinsed with 200 ml PBS and 50 ml 0.5 M NaCl. The IgGs bound to the column were eluted with 0.15 M glycine buffer, pH 2.5. The eluate was dialyzed against 2,000 volumes of PBS overnight and concentrated by reverse dialysis in Ficoll type 400 (Pharmacia LKB Biotechnology AB, Uppsala, Sweden).
Binding Studies
The analysis of IgG interaction with LDL was performed using a micro enzyme-linked immunosorbent assay (ELISA) technique. The plates (Costar, Cambridge, Mass.) were coated with LDL (1 fig/ well) at 20°C overnight. Delipidation of LDL was performed with a hexane/isopropanol mixture (3:2, vol/vol) for 1 hour at 20°C. 31 The plates were blocked for 1 hour with PBS containing 1% BSA, 0.05% Tween-20 (BSA-Tween-PBS). After a fourfold rinsing with PBS, the series of IgG dilutions in BSATween-PBS were placed into the wells. Plates were incubated for 6 hours, washed with BSA-Tween-PBS, and combined with anti-human IgG antibodies conjugated with peroxidase and incubated for 1 hour. Then, plates were rinsed, and 100 ^.1 substrate (0.1 mg/ml o-phenylenediamine and 0.003% H 2 O 2 in 50 mM citrate buffer, pH 4.7) was added into the wells. The reaction was stopped by addition of 20 fi\ 50% sulfuric acid. The optical density was measured at 492 nm using a Titertek Multiskan automatic microphotometer from Eflab Oy, Helsinki, Finland.
Affinity Constant
The affinity constant of IgG to LDL was measured using ). The same LDL dilutions incubated in the absence of affinity-purified IgG were used as controls. To immobilize the immune complex of IgG with LDL formed after an overnight incubation, the plates were rinsed with BSA-Tween-PBS with subsequent determination of radioactivity in each well. The identical procedures were performed in the presence of 0.001-1 mg/ml unlabeled LDL. The affinity constant (K,) was calculated according to Muller, 32 proceeding from the known amounts of the radioactive and non-radioactive LDL added as well as the amount of 125 I-LDL bound by IgG.
Immunoglobulin G Isoelectrofocusing and Native Blot
Isoelectrofocusing of IgG was performed according to Reinhart and Malamund. 33 Seventy micrograms IgG was focused in 5% polyaciylamide gel containing 4.5 M urea, 2.5% Nonidet P-40, and 2% (wt/vol) Pharmalyte, pH 3-10 (Pharmacia). The transfer of IgG separated by the charge from gel to the LDLcoated and the Tween-, BSA-, and gelatin-blocking nitrocellulose occurred via passive diffusion in a rising flow of PBS containing 0.3% BSA and 0.05% Tween-20 over 4 hours. After the termination of transfer, the replica was rinsed many times with large volumes of 50 mM Tris HC1, pH 7.5, containing 0.5 M NaCl, 0.3% BSA, and 0.05% Tween-20. The replica was treated with the antibodies against human IgG conjugated with peroxidase and revealed with 4-chloro-l-naphthol with H 2 O 2 as described above. 2 Fragments F(ab') 2 fragments of IgG were obtained by pepsin degradation with subsequent purification using Sephadex G-150. 35 -3 * F(ab')2 fragments of IgG derived from healthy donors and CHD patients were labeled witĥ I 3 6 and added to the LDL-coated plates (10 ng apo B/well) in the concentration of 0.01-10 jig/ml. After a 6-hour incubation, plates were rinsed with BSATween-PBS, and the radioactivity was measured.
F(ab')
Clq Component of Complement
LDL (30 tig/ml) was incubated for 6 hours with 30 )u,g/ml of the total IgG fraction or 30 /ig/ml of anti-LDL obtained from the blood of patients. After that, 30 jig/ml ^I-Clq 36 was added, and incubation was continued for another 4 hours. After the incubation, the samples were supplemented with an equal volume of 5% polyethyleneglycol 6000 and incubated for 18 hours. Samples were centrifuged for 15 minutes at 4,000 rpm, and the sediment was rinsed with 2.5% polyethyleneglycol 6000 with subsequent determination of its radioactivity.
Statistical Analysis
The significance of differences was evaluated by dispersion analysis methods using a BMDP statistical program package. 37 
Results
Isolation and Characteristics of Immunoglobulin Gs Interacting With Low Density Lipoprotein
First, we have attempted to demonstrate the presence of IgGs interacting with LDL in the serum of CHD patients and the serum of healthy subjects. Using immunoblotting, it has been confirmed that IgGs interacting with apo B, apoproteins of LDL, are present in the serum of CHD patients ( Figure 1A ). donor serum was very weak ( Figure IB ). Since the sera of patients and healthy subjects were characterized by approximately equal apo B contents, this weak reaction may be explained by a lower content of antibodies against lipoprotein in the serum of healthy donors.
To isolate the antibodies against LDL (anti-LDL) from the serum, at the first stage total IgG fractions were obtained. The yield of IgG resulting from the two isolation procedures, that is, precipitation with ammonium sulfate and ion-exchange chromatography, was about 50% (Table 1) . Anti-LDL IgGs were purified from the total IgG fractions by affinity chromatography on a column with immobilized LDL. The amount of anti-LDL IgG isolated from the sera of patients accounted for 0.14% of the total IgG content in the serum. On the other hand, affinity chromatography of the total IgG fraction obtained from sera of healthy donors allowed us to isolate a 30-fold lower amount of IgG (<0.005% of the total IgG content in the serum). IgG, immunoglobulin G; CHD, coronary heart disease. Figure 2 shows separation of the total IgG fraction by isoelectrofocusing. Subsequent immunoblotting with LDL revealed that in the total IgG fraction of CHD patients, only the Igs with an isoelectric point (pi) of about 8.5 (8.1-9.0) intensively bind LDL (Figures 2 and 3 ). IgG with a pi of approximately 8.5 obtained from the sera of healthy subjects bound the lipoprotein much less effectively (Figures 2 and 4) . Anti-LDL IgGs purified from the total IgG fraction of patients' sera by affinity chromatography are represented by several bands with pis of about 8.5 ( Figure 3) .
To test the specificity of anti-LDL IgG isolated on LDL-Sepharose, we performed immunoblotting with electrophoretically separated serum proteins. Affinity-purified LDL bound only to the apo B band but to no other serum proteins ( Figure 1C ).
The F(ab') 2 fragments obtained from affinity-purified anti-LDL IgG had an ability to bind LDL (Figure 4) . F(ab') 2 fragments from the total IgG fraction of healthy donors were devoid of this ability (Figure 4) . from the blood of healthy donors did not lead to marked Clq binding either. Thus, affinity-purified anti-LDL IgGs bind to LDL apo, but not to other blood serum proteins. F(ab') 2 fragments of these IgGs also possess an ability to bind to LDL. Finally, the LDL-IgG complex binds the Clq component of complement. All these data indicate that the anti-LDL IgG affinity purified on LDL-Sepharose from the total IgG fraction of patients' sera are antibodies against LDL (anti-LDL).
FIGURE 2. Photograph showing separation by isoelectrofocusing (lanes 1 and 2) and immunoblotting (lanes 3 and 4) of the total immunoglobulin G (IgG) fraction derived from the blood of healthy subjects (lanes 2 and 4) and coronary heart disease patients (lanes 1 and 3). Isoelectrofocusing and transfer onto nitrocellulose coated with low density lipoprotein were performed as described in "Methods." Replica was treated with peroxidase-labeled antibodies against human IgG and revealed with 4-chloro-l-naphthol with
No significant differences in the interaction of antibodies with native LDL and lipoprotein delipidated by hexane/isopropanol were found, suggesting that isolated anti-LDLs are antibodies against the protein moiety of the lipoprotein particle ( Figure 6 ). Table 2 shows the affinity constants of purified anti-LDL to lipoproteins. The affinity constants for native LDL and Lp(a) obtained from the blood of a 
I-F(ab') 2 fragments (dpm/well [10~3]) obtained from affinity-purified anti-LDL immunoglobulin G (IgG, ug/ml) (1) and the total IgG fraction obtained from the blood of healthy subjects (2). l25 I-F(ab') 2 fragments obtained by pepsin treatment were added to LDL-coated wells and incubated over 6 hours. After incubation, wells were washed, and the radioactivity was measured.
FIGURE 5. Bar graph showing binding of the 125 I-Clq complement component (dpm/probe) by low density lipoproteinimmunoglobulin G (LDL-IgG) complex. 125 I-Clq complement component was incubated over 4 hours in the presence of LDL (1), LDL + total IgG fraction from the blood of healthy subjects (2), and LDL + affinity-purified IgG (3). Immune complexes were precipitated by polyethylene glycol 6000, after which the radioactivity of the precipitate was measured. Amounts ofClq, LDL, and IgG are indicated in "Methods." Data are represented as mean±SEM of three independent experiments.
healthy donor as well as for glycosylated LDL, acetylated LDL, and LDL oxidized by Cu 2+ were similar. The antibodies show a higher affinity for LDL isolated from the blood of CHD patients as well as MDA-modified LDL. The LDL desiarylated in vitro by neuraminidase had the highest affinity constant among the modified lipoproteins.
Effect of Anti-Low Density Lipoprotein on the Low Density Lipoprotein-lnduced Accumulation of Cellular Lipids
Patients' blood sera caused a more than twofold increase in total cholesterol in cultured cells of human aortic intima, while the blood sera of healthy donors proved to be ineffective in this respect (Table 3) .
LDL isolated from plasma of healthy donors failed to stimulate the deposition of intracellular cholesterol, although in combination with the total IgG fraction derived from the patients' serum, LDL caused a twofold increase in cholesterol content in cultured cells. The total IgG fraction of healthy donor plasma had no effect on LDL-mediated cholesterol accumulation (Table 3) .
Addition of affinity-purified anti-LDL to the cells cultured with the LDL of healthy donors substantially increased the cellular cholesterol content starting with the concentration of 25 fig/ml (Table 4) . Anti-LDL brought about an increase in triglycerides 
FIGURE 6. Line plot showing binding of antibodies with native (1 and 3) and delipidated (2 and 4) low density lipoprotein (LDL, tiglml) measured as absorbance (A) at 492 nm from the blood of healthy subjects (1 and 2, o) and coronary heart disease patients (3 and 4, 9). The plate wells were coated with LDL (1 fig protein/well). Delipidation of LDL was performed with a hexane/isopropanol mixture (3-2, volfvol). The interaction of anti-LDL with native and delipidated LDL was performed by enzyme-linked immunosorbent assay as described in "Methods."
and free and esterified cholesterol, while phospholipid levels remained unchanged (Table 5 ). Native LDL of healthy donors taken without anti-LDL did not induce lipid accumulation in cultured cells. LDL isolated from patients' sera was capable of inducing lipid accumulation in cultured cells; however, anti- Data from one of three representative experiments are presented. The affinity constant of anti-LDL was determined using native and modified ^I-LDL of known specific activity (200-1,000 cpm/ng apolipoprotein B). Known amounts of added radioactive and nonradioactrve LDL and the amount of 1S I-LDL bound to anti-LDL were used to calculate the affinity constant LDL, low density lipoprotein; HD LDL, healthy donors' LDL; Lp(a), lipoprotein(a); MDA, malondialdehyde; Pt LDL, coronary heart disease patients' LDL.
•Significant difference from HD LDL (p<0.05). Values listed are mean of four to six determinations ±SEM. Cells were isolated by collagenase dispersion from subendothelial part of human aortic intima. Sera, LDL, and IgG preparations were added to cultured cells on the 7th day in primary culture. Twenty-four hours later, cells were rinsed and extracted by chloroform/methanol, and cellular cholesterol was determined using a commercial kit as described in "Methods." 'Significant difference from control (/?<0.05).
LDL enhanced this property of patients' LDL starting with a concentration of 10 /ig/ml ( Table 4 ). The effects of anti-LDL were dose dependent and reached a maximum at a concentration of 50 /u,g/ml. Thus, anti-LDLs alter initially native LDLs of healthy donors, imparting to them an ability to induce the accumulation of cellular lipids and, on the other hand, enhance this property of LDL of atherosclerotic patients. The IgG of patients that do not interact with LDL (not adsorbed on LDL-Sepharose) failed to increase cholesterol accumulation in cultured cells (Table 4) . The effect of anti-LDL on the cellular metabolism of lipoprotein was assessed by the uptake (surfacebound and internalized LDL) and degradation of 125 I-LDL by cultured intimal cells. The uptake of CHD patients' LDL was nearly twofold higher than that of healthy donors' LDL; at the same time, degradation of patients' LDL was significantly lower as compared with the degradation of healthy donors' LDL ( Table 6 ). Addition of anti-LDL to cultured cells increased nearly 2.5-fold the uptake of both healthy donors' LDL and patients' LDL. Anti-LDL also increased the lipoprotein degradation, although to a lesser degree (Table 6) .
We have investigated the effect of certain components of circulating immune complexes on the accumulation of cellular cholesterol. The Clq component of complement, added together with anti-LDL, caused a nearly threefold LDL-mediated increase in intracellular cholesterol, whereas anti-LDL in the absence of Clq caused a less than twofold increase (Table 7 ). An even greater rise of cholesterol level was observed when the culture containing LDL was supplemented with fibronectin in addition to anti-LDL and Clq. It should be pointed out that neither fibronectin nor Clq in the absence of anti-LDL stimulated the accumulation of cellular cholesterol (Tables 7 and 8 ). Combined addition of anti-LDL, Clq, and fibronectin to culture increased the uptake and degradation of LDL (Table 8 ). Addition of Clq and fibronectin to cell culture in the absence of anti-LDL had no effect on lipoprotein metabolism (Table 8) .
Discussion From the blood of CHD patients, we have isolated IgGs having affinity to the protein moiety of the LDL particle. The content of such IgGs in the blood of healthy donors was much lower than in the patients' blood. A high specificity of LDL to apo, a high affinity constant to LDL, the ability of F(ab') 2 fragments to bind to lipoprotein, and binding of the Clq component of complement by IgG-LDL complexes allows us to conclude that the isolated IgGs are autoantibodies against LDL.
We are not the first investigators to indicate the presence of antibodies against LDL in human blood. Earlier, the antibodies against lipoproteins or LDLbinding factors were found in the patients suffering from different diseases as well as in healthy sub- 68±6  86±9  129±14t  150±14t  143±14f  63±5   119±13   138±18  142±14  187±18t  249±18t  306±29t  290±24t  133±10 LDS, lipoprotein-deficient serum; LDL, low density lipoprotein; IgG, immunoglobulin G. LDL of healthy donors was used. Other details are the same as in Table 3 .
•Residual IgGs are immunoglobulins of patients that do not interact with LDL (not adsorbed on LDL-Sepharose). tSignificant difference from LDL (p<0.05). LDL, 100 /tg/ml; anti-LDL, 50 /ig/ml. Other details are the same as in Table 3 .
•Significant difference from control (p<0.05).
jects. 38 " 43 In 1965, Beaumont 44 described a situation in which hyperlipidemia, xanthomatosis, and atherosclerosis were apparently associated with anti-/3-lipoprotein antibodies. Subsequently, the presence of antibodies against LDL in the blood of patients with coronary atherosclerosis and its clinical manifestations was confirmed by other studies. 39 " 43 It was demonstrated that Igs are major LDL binding proteins in human plasma. 45 The antibodies isolated in this study had a higher affinity to the LDL of CHD patients that to the LDL of healthy donors. This fact corroborates our recent finding that patients' LDL differs from native LDL of healthy donors. Recently, we 7 ' 8 have shown that LDL obtained from the plasma of atherosclerotic patients and causing the accumulation of cellular lipids has a much lower content of sialic acid as compared with native LDL of healthy donors and that desialylation of native lipoprotein leads to the accumulation of cellular lipids. This fact well agrees with the finding that in this study, the antibodies isolated from the blood of patients had the highest affinity to LDL desialylated with neuraminidase. Apparently, in atherosclerotic patients autoantibodies against LDL are produced in response to the emergence of desialylated lipoproteins in the bloodstream. The detection of antibodies with a high affinity to desialylated LDL in patients' blood serum is a strong argument in favor of the presence of desialylated LDL in patients' blood.
It cannot be ruled out that not only desiarylation but other types of LDL modification might be responsible for the formation of autoantibodies against LDL. Immunization of animals with homologous LDL modified in different ways leads to the emergence of specific antibodies to methylated, ethylated, acetylated, carbamylated, and glycosylated lipoproteins. 46 - 48 Autoantibodies against homologous LDL modified by MDA were found in the blood of animals with experimentally induced atherosclerosis and in the blood of atherosclerotic patients, while antibodies against glycosylated LDL were detected in the blood of patients suffering from diabetes mellitus. 49 " 51 In the present study, we have found that anti-LDLs isolated from the blood of atherosclerotic patients have a higher affinity to MDA-LDL than to native LDL. It should also be pointed out that the antibodies isolated in this study represent a mixture of several IgG subtractions with variable charge. One may assume that the antibodies with a different charge and possibly other variable characteristics have a different affinity to different sites of both native and modified lipoproteins. It is also possible that the amount and the ratio of certain antibody subtractions vary in different CHD patients.
Igs and other components of immune complexes are accumulated in the vessel wall, and this deposition is most prominent at the site of an atherosclerotic plaque. 52 - 57 Certain evidence indicates that Igs LDL of healthy donors was used. Other details are the same as in Table 3. •Significant difference from control (p<0.05). 39 The present study demonstrates that autoantibodies against modified LDL circulating in the blood of atherosclerotic patients substantially increase the ability of this lipoprotein to induce the deposition of intracellular fat. In addition, by interacting with initially native LDL of healthy donors, these antibodies make LDLs capable of inducing the accumulation of intracellular cholesterol. We assume that immune complexes containing LDL penetrate into intimal cells past specific receptors for LDL. Recently, we 8 have shown that the aggregation of modified LDL occurring under cell culture conditions is a necessary prerequisite for the accumulation of intracellular lipids caused by modified LDL. Furthermore, according to our data, LDL insolubilization brought about by the formation of an insoluble LDL associate with different agents, including immune complexes, leads to the accumulation of intracellular lipids. 26 We assume that the LDL-containing immune complex that stimulates the accumulation of lipids is transported inside the cell via phagocytosis. Earlier, we 25 * 26 have shown that cultured intimal cells are no less phagocytic than peritoneal macrophages. Within the immune complex, LDLs are taken up and degraded much more effectively than free lipoprotein. Capacity of the LDL-IgG complex to cause intracellular lipid accumulation is considerably increased after addition of other components of circulating immune complexes, that is, Clq and fibronectin, which are present in the plasma and in the vessel. he relation between immunological mechanisms and atherosclerosis has been attracting the attention of many researchers for a long time.
3861 - 54 Among various aspects of this relation, a special role in the pathogenesis of atherosclerosis was attributed to antibodies against LDL, giving rise to the autoimmune hypothesis of atherogenesis. 3862 - 64 The purpose of this study was not to confirm or to refute the existing hypotheses, although our data suggest that antibodies against LDL might play the role of a major factor of blood plasma responsible for foam cell formation. Our results give reasons to assume that the primary factor present in the blood plasma of atherosclerotic patients is modified LDL (desialylated or, possibly, glycosylated or subjected to other types of modification). The second plasma factor is represented by autoantibodies produced in response to the emergence of modified LDL.
